Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.lfs.2020.117627 http://scihub22266oqcxt.onion/10.1016/j.lfs.2020.117627 32251634!7194560!32251634     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Life+Sci 2020 ; 251 (ä): 117627 Nephropedia Template TP {{tp|p=32251634|t=2020. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease |pdf=|usr=}}{{32251634}} gab.com Text Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease JO: Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32251634 #FOAvip AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment. Twit Text FOAVip Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease ????Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32251634 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32251634 #FOAvip English Wikipedia <ref>{{Cite pmid|32251634}}</ref> Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease #MMPMID32251634 Kandeel M; Al-Nazawi M Life Sci 2020[Jun]; 251 (ä): 117627 PMID32251634show ga AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment. |*Drug Evaluation, Preclinical[MESH] |*Drug Repositioning[MESH] |*Molecular Docking Simulation[MESH] |Amino Acid Sequence[MESH] |Antiviral Agents/*chemistry/pharmacology[MESH] |Betacoronavirus/*enzymology[MESH] |Binding Sites[MESH] |Coronavirus 3C Proteases[MESH] |Curcumin/chemistry/pharmacology[MESH] |Cysteine Endopeptidases/*chemistry[MESH] |Drug Approval[MESH] |Hydrogen Bonding[MESH] |Hydrophobic and Hydrophilic Interactions[MESH] |Middle East Respiratory Syndrome Coronavirus/enzymology[MESH] |Models, Molecular[MESH] |Protease Inhibitors/*chemistry/pharmacology[MESH] |SARS-CoV-2[MESH] |Sequence Alignment[MESH] |Severe acute respiratory syndrome-related coronavirus/enzymology[MESH] |United States[MESH] |United States Food and Drug Administration[MESH]Virtual screening and repurposing of FDA approved drugs against COVID-(epmc).pdf DeepDyve Pubget Overpricing